JP6696838B2

JP6696838B2 - Interior material and manufacturing method thereof

Info

Publication number: JP6696838B2
Application number: JP2016119721A
Authority: JP
Inventors: 鈴木　昭夫; 昭夫鈴木; 隆弘上野; 友彦樋口; 原賀　久人; 久人原賀; 永吉　英昭; 英昭永吉
Original assignee: Takazono Corp; Fujico Co Ltd
Current assignee: Takazono Corp; Fujico Co Ltd
Priority date: 2016-06-16
Filing date: 2016-06-16
Publication date: 2020-05-20
Anticipated expiration: 2036-06-16
Also published as: JP2017221914A

Description

本発明は、例えば、抗がん剤の製剤に使用する安全キャビネットの内側面と外側面、安全キャビネットが設置される製剤室、ナースステーション、外来化学療法室、処置室、廊下、病室、洗面所、トイレ等の抗がん剤（抗がん剤の分解過程における中間生成物を含む）に曝露される空間に露出させて使用される内装材及びその製造方法に関する。 INDUSTRIAL APPLICABILITY The present invention is, for example, an inner surface and an outer surface of a safety cabinet used for preparation of an anticancer agent, a preparation room in which the safety cabinet is installed, a nurse station, an outpatient chemotherapy room, a treatment room, a corridor, a hospital room, and a washroom. The present invention relates to an interior material used by being exposed in a space exposed to an anticancer agent (including an intermediate product in a decomposition process of an anticancer agent) such as a toilet, and a manufacturing method thereof.

抗がん剤は、健康な人には健康被害を起こす危険薬剤であるため、抗がん剤の調製に使用する安全キャビネットに関しては、安全キャビネットの使用後に抗がん剤を失活させて除去する処理方法のガイドラインが発行されている。しかし、ガイドラインに示された処理方法は、非常に煩雑である。また、抗がん剤は種類によっては分解され難いものがあるため、ガイドラインに示された処理方法を用いて多種類の抗がん剤を一様に失活するには限界があるといった問題を有している。
そこで、二酸化チタンを含む光触媒水性組成物を抗がん剤が付着した対象物上に噴霧し、ブラックライト蛍光灯から紫外線（波長３１５〜３８０ｎｍ）を照射して二酸化チタンに光触媒活性を発現させ、抗がん剤を分解する（抗がん剤を除染する）ことが提案されている（例えば、特許文献１参照）。 Since the anti-cancer drug is a dangerous drug that causes health damage to healthy people, regarding the safety cabinet used for preparing the anti-cancer drug, deactivate and remove the anti-cancer drug after using the safety cabinet. Guidelines on how to process are issued. However, the processing method shown in the guideline is very complicated. In addition, since some anticancer agents are difficult to decompose depending on the type, there is a limit to uniformly deactivating many types of anticancer agents using the treatment method shown in the guidelines. Have
Therefore, a photocatalytic aqueous composition containing titanium dioxide is sprayed onto an object to which an anticancer agent is attached, and ultraviolet rays (wavelength 315 to 380 nm) are irradiated from a black light fluorescent lamp to cause titanium dioxide to exhibit photocatalytic activity, It has been proposed to decompose the anticancer drug (decontaminate the anticancer drug) (see, for example, Patent Document 1).

特許第５６１３９００号公報Japanese Patent No. 5613900

抗がん剤の曝露による人への影響は、抗がん剤の製剤時に限定されるものではなく、抗がん剤を取扱う場合（例えば、運搬及び保管、投与、使用後の回収及び破棄等）において生じる。更に、抗がん剤の投与を受けた患者の息や排泄物中にも抗がん剤が含まれているため、医療現場（特にがん病棟）においては、抗がん剤の曝露による医療スタッフや、自宅治療のがん患者の家族への影響は、場所や時間の制約を受けず発生していることになる。
ここで、特許文献１に記載された二酸化チタンは、環境（人を含む）に与える影響がないという利点を有するが、抗がん剤の分解を行う場合は二酸化チタンに紫外線を照射する必要があるため、安全キャビネット内のように紫外線の照射が可能な空間に対しては無人状態で適用できるが、製剤室、ナースステーション、外来化学療法室、処置室、廊下、病室、洗面所、トイレといった紫外線の照射が自由にできない空間に適用する際には、大きな制約が生じるという問題がある。 The effects on humans due to exposure to anti-cancer drugs are not limited to the preparation of anti-cancer drugs, but when dealing with anti-cancer drugs (for example, transportation and storage, administration, collection and disposal after use, etc.). ) Occurs in. Furthermore, since the anti-cancer drug is contained in the breath and excretion of patients who receive the anti-cancer drug, medical treatment by exposure to the anti-cancer drug is performed in the medical field (especially in the cancer ward). The effects of staff and home treatment on the families of cancer patients are occurring regardless of location and time.
Here, the titanium dioxide described in Patent Document 1 has an advantage that it does not affect the environment (including humans), but it is necessary to irradiate the titanium dioxide with ultraviolet rays when decomposing the anticancer agent. Therefore, it can be applied unmanned to a space that can be irradiated with ultraviolet rays, such as in a safety cabinet, but it can be used in preparation rooms, nurse stations, outpatient chemotherapy rooms, treatment rooms, corridors, hospital rooms, washrooms, toilets, etc. There is a problem that a large limitation occurs when it is applied to a space where ultraviolet rays cannot be freely irradiated.

また、特許文献１に記載された方法では、光触媒水性組成物を安全キャビネットの内壁面と作業台に噴霧して二酸化チタンを付着させているため、安全キャビネットを繰り返し使用していると、付着させた二酸化チタン粒子が徐々に剥離して消失する。このため、安全キャビネット内で抗がん剤の分解を確実に実施しようとすると、例えば、一定期間使用すると光触媒水性組成物を噴霧して、安全キャビネットの内壁面と作業台に一定量の二酸化チタンが付着している状態を維持しなければならず、安全キャビネットの保守管理の負担が大きいという問題がある。 Further, in the method described in Patent Document 1, since the photocatalyst aqueous composition is sprayed on the inner wall surface of the safety cabinet and the workbench to deposit titanium dioxide, the titanium dioxide is deposited when the safety cabinet is repeatedly used. The titanium dioxide particles gradually exfoliate and disappear. For this reason, when it is attempted to reliably decompose the anticancer drug in the safety cabinet, for example, when used for a certain period, the photocatalytic aqueous composition is sprayed, and a certain amount of titanium dioxide is sprayed on the inner wall surface of the safety cabinet and the workbench. However, there is a problem in that the maintenance and management of the safety cabinet is heavy.

本発明はかかる事情に鑑みてなされたもので、抗がん剤を吸着し、可視光による光触媒作用により分解することが長期間安定して可能な内装材及びその製造法を提供することを目的とする。 The present invention has been made in view of the above circumstances, and an object thereof is to provide an interior material capable of adsorbing an anticancer agent and decomposing by a photocatalytic action by visible light stably for a long period of time, and a manufacturing method thereof. And

前記目的に沿う第１の発明に係る内装材は、基材と、該基材の表面に固着され、可視光の照射により光触媒活性を発現する二酸化チタン粒子を有する、厚さが０．５〜３μｍの多孔質皮膜とを備え、
前記多孔質皮膜には前記二酸化チタン粒子が露出し、存在する抗がん剤に曝露される。 Interior material according to the first invention along the object is fixed and the substrate, the surface of the substrate, having titanium dioxide particles expressing a photocatalytic activity by irradiation of visible light, is 0.5 thick With a 3 μm porous film,
The titanium dioxide particles are exposed in the porous film and exposed to the existing anticancer agent.

前記目的に沿う第２の発明に係る内装材の製造方法は、基材と、表側が抗がん剤に曝露される空間に露出し、裏側が前記基材の表面に固着している多孔質皮膜とを有する内装材の製造方法であって、
二酸化チタン粒子と金属化合物とを有する混合物を溶射フレーム中に供給して該混合物を該溶射フレームの流れに乗せ、前記金属化合物の加熱変化で生成した電子供与体を前記二酸化チタン粒子の表面に担持させながら、前記電子供与体を担持した前記二酸化チタン粒子を前記基材の表面に衝突させて、厚さが０．５〜３μｍの前記多孔質皮膜を形成し、
前記多孔質皮膜に対する封孔を防止して、該多孔質皮膜の形成時の多孔質状態を維持することにより該多孔質皮膜に前記電子供与体を担持した前記二酸化チタン粒子を露出させる。 A method for producing an interior material according to a second aspect of the invention, which is in accordance with the above object, is a porous material in which a base material and a front side are exposed in a space exposed to an anticancer agent and a back side is fixed to a surface of the base material. A method of manufacturing an interior material having a film,
A mixture containing titanium dioxide particles and a metal compound is supplied into a flame spraying frame, the mixture is placed on the flow of the flame spraying frame, and an electron donor produced by the heating change of the metal compound is supported on the surface of the titanium dioxide particles. While colliding, the titanium dioxide particles carrying the electron donor are made to collide with the surface of the base material to form the porous film having a thickness of 0.5 to 3 μm ,
The titanium dioxide particles carrying the electron donor are exposed in the porous film by preventing the pores from sealing the porous film and maintaining the porous state at the time of forming the porous film.

第１の発明に係る内装材においては、内装材が、基材と、基材の表面に固着された多孔質皮膜とを備えるので、抗がん剤に曝露される空間を囲む部材の表面に内装材の基材側を取付けることにより、抗がん剤に曝露される空間に多孔質皮膜を容易に露出させることができる。
また、基材の材質及び形状を選択することにより、内装材の使用場所、内装材の施工方法に応じて最適な内装材を作製することができる。このため、内装材は、抗がん剤に曝露されていた空間、例えば、既存の製剤室、ナースステーション、外来化学療法室、処置室、廊下、病室、洗面所、トイレ等に対しても、容易に取付けることができる。 In the interior material according to the first aspect of the present invention, since the interior material includes the base material and the porous film adhered to the surface of the base material, the interior material is provided on the surface of the member surrounding the space exposed to the anticancer agent. By attaching the base material side of the interior material, the porous film can be easily exposed in the space exposed to the anticancer agent.
Further, by selecting the material and shape of the base material, an optimum interior material can be produced according to the place of use of the interior material and the method of applying the interior material. Therefore, the interior material is a space that has been exposed to anti-cancer agents, for example, existing formulation room, nurse station, outpatient chemotherapy room, treatment room, corridor, hospital room, washroom, toilet, etc. Can be easily installed.

第１の発明に係る内装材においては、抗がん剤に曝露される空間に多孔質皮膜が露出しているので、抗がん剤を効率的に吸着することができ、空間内の抗がん剤の濃度を低減することができると共に、抗がん剤の拡散を抑制することができる。
また、多孔質皮膜に露出している二酸化チタン粒子は、可視光の照射により光触媒活性を発現するので、日中は自然光（太陽光）や照明器具からの照明光により、夜間は照明器具からの照明光により、多孔質皮膜に吸着した抗がん剤を分解して失活することができる。
更に、吸着した抗がん剤の分解は多孔質皮膜の表層部（表面から可視光が進入する範囲）に限られるが、表層部の抗がん剤が分解されると表層部と内部との間に抗がん剤の濃度勾配が発生し、内部の抗がん剤は表層部に移動して分解される。このため、内装材（多孔質皮膜）内に抗がん剤が蓄積されることはなく、内装材（多孔質皮膜）の抗がん剤に対する吸着能力を維持することができる。 In the interior material according to the first aspect of the invention, since the porous film is exposed in the space exposed to the anti-cancer agent, the anti-cancer agent can be efficiently adsorbed, and the anti-cancer agent in the space is The concentration of the cancer drug can be reduced and the diffusion of the anticancer drug can be suppressed.
In addition, the titanium dioxide particles exposed in the porous film exhibit photocatalytic activity by irradiation with visible light, so natural light (sunlight) or illumination light from lighting equipment during the daytime and lighting from lighting equipment at night The illumination light can decompose and deactivate the anticancer agent adsorbed on the porous film.
Further, the decomposition of the adsorbed anticancer agent is limited to the surface layer part of the porous film (the range where visible light enters from the surface), but when the surface layer part is decomposed, A concentration gradient of the anticancer drug is generated during this period, and the internal anticancer drug moves to the surface layer and is decomposed. Therefore, the anticancer agent is not accumulated in the interior material (porous film), and the adsorption capacity of the interior material (porous film) for the anticancer agent can be maintained.

第２の発明に係る内装材の製造方法においては、基材の表面に、溶射により多孔質皮膜を形成するので、溶射条件を調整することにより、多孔質皮膜の厚みと多孔質状態（比表面積、気孔の径）を容易に制御することができる。 In the method for producing an interior material according to the second aspect of the invention, since the porous coating is formed on the surface of the base material by thermal spraying, the thickness and porous state (specific surface area) of the porous coating can be adjusted by adjusting the thermal spraying conditions. , Pore diameter) can be easily controlled.

本発明の一実施の形態に係る内装材の断面の説明図である。It is explanatory drawing of the cross section of the interior material which concerns on one embodiment of this invention. 実施例１におけるフルオロウラシルの分解状況を示すグラフである。5 is a graph showing the decomposition state of fluorouracil in Example 1. 実施例２におけるシクロホスファミドの分解状況を示すグラフである。3 is a graph showing the decomposition state of cyclophosphamide in Example 2. 実施例３におけるパクリタキセルの分解状況を示すグラフである。9 is a graph showing the decomposition status of paclitaxel in Example 3. 実施例４におけるドキソルビシン塩酸塩の分解状況を示すグラフである5 is a graph showing the decomposition state of doxorubicin hydrochloride in Example 4.

続いて、添付した図面を参照しつつ、本発明を具体化した実施の形態につき説明し、本発明の理解に供する。
図１に示すように、本発明の一実施の形態に係る内装材１０は、基材１１と、基材１１の表面に固着され、可視光の照射により光触媒活性を発現する二酸化チタン粒子１２を有する多孔質皮膜１３とを備え、多孔質皮膜１３の表面には二酸化チタン粒子１２が露出し、抗がん剤に曝露される。以下、詳細に説明する。 Subsequently, embodiments of the present invention will be described with reference to the accompanying drawings to provide an understanding of the present invention.
As shown in FIG. 1, an interior material 10 according to an embodiment of the present invention comprises a base material 11 and titanium dioxide particles 12 fixed to the surface of the base material 11 and exhibiting photocatalytic activity by irradiation of visible light. The porous film 13 is provided, and the titanium dioxide particles 12 are exposed on the surface of the porous film 13 and exposed to the anticancer agent. The details will be described below.

内装材１０が、基材１１と、基材１１の表面に固着された多孔質皮膜１３とを備えるので、抗がん剤に曝露される空間を囲む部材（例えば、安全キャビネットでは内壁面と作業台、調剤室等の部屋では天井板、壁板、床板）の表面に基材１１側を当接させて取付けることにより、抗がん剤に曝露される空間に内装材１０の多孔質皮膜１３を露出させることができる。その結果、多孔質皮膜１３の表面は、多孔質皮膜１３を形成している二酸化チタン粒子１２が露出している状態となる。 Since the interior material 10 includes the base material 11 and the porous film 13 adhered to the surface of the base material 11, a member surrounding the space exposed to the anticancer agent (for example, an inner wall surface and a work surface in a safety cabinet). In a room such as a table or a dispensing room, the base material 11 side is brought into contact with and attached to the surface of a ceiling plate, a wall plate, or a floor plate, so that the porous film 13 of the interior material 10 is provided in the space exposed to the anticancer agent. Can be exposed. As a result, the surface of the porous film 13 is in a state where the titanium dioxide particles 12 forming the porous film 13 are exposed.

基材１１としては、例えば、タイル、衛生陶器、ガラス、鏡、コンクリート製の部材（例えば、板、棒、ブロック）、樹脂製の部材（例えば、板、棒、ブロック、フィルム）、金属製の部材（例えば、板、棒、ブロック、フィルム）、天然繊維及び化学繊維のいずれか一方又は双方を組み合わせた複合繊維て形成した織物（三次元織物も含む）や不織布等の成形品等が挙げられる。このため、基材１１の材質及び形状を選択することにより、内装材１０の使用場所、内装材１０の施工方法に応じて最適な内装材を作製することができる。特に、シート状の基材１１を用いることにより、内装材１０の裁断、折り曲げ、接着等の加工を容易に行うことができ、内装材１０の施工性を向上させることができる Examples of the base material 11 include tiles, sanitary ware, glass, mirrors, concrete members (for example, plates, rods, blocks), resin members (for example, plates, rods, blocks, films), and metal members. Examples include members (for example, plates, rods, blocks, films), woven fabrics (including three-dimensional woven fabrics) and non-woven fabrics formed from composite fibers obtained by combining one or both of natural fibers and chemical fibers, and the like. .. Therefore, by selecting the material and shape of the base material 11, it is possible to manufacture an optimum interior material according to the place of use of the interior material 10 and the construction method of the interior material 10. In particular, by using the sheet-shaped base material 11, it is possible to easily perform processing such as cutting, bending, and bonding of the interior material 10, and it is possible to improve the workability of the interior material 10.

基材への溶射により種々の厚さの多孔質皮膜を形成し、基材上に形成された多孔質皮膜を観察した結果、多孔質皮膜の厚さが０．５μｍ未満では基材の表面が部分的に露出する状況が確認された。一方、多孔質皮膜の厚さが３μｍを超えると、多孔質皮膜の内部応力が大きくなり、基材から多孔質皮膜がはがれ易くなる。また、多孔質皮膜の奥側まで光が十分に届かず不十分な分解反応に起因する中間生成物が発生するという問題が生じる。このため、内装材１０の多孔質皮膜１３の厚さＴを０．５〜３μｍの範囲に設定した。 As a result of observing the porous film formed on the substrate by forming a porous film of various thicknesses by thermal spraying on the substrate, the surface of the substrate was found to be low when the thickness of the porous film was less than 0.5 μm. The situation of partial exposure was confirmed. On the other hand, when the thickness of the porous coating exceeds 3 μm, the internal stress of the porous coating increases, and the porous coating easily peels from the base material. In addition, there is a problem that light does not reach the inner side of the porous film sufficiently and an intermediate product is generated due to insufficient decomposition reaction. Therefore, the thickness T of the porous film 13 of the interior material 10 is set in the range of 0.5 to 3 μm.

多孔質皮膜の比表面積を変えて内装材を作製し、抗がん剤の吸着性能と、多孔質皮膜の摩耗耐久性をそれぞれ評価した。その結果、多孔質皮膜の比表面積が１０ｍ^２／ｇ未満では抗がん剤の吸着性能が低く、多孔質皮膜の比表面積が１０ｍ^２／ｇ以上では、比表面積の増加に伴って抗がん剤の吸着性能が向上することが確認できた。一方、多孔質皮膜の摩耗耐久性は、比表面積の増加に伴って低下する傾向を示し、比表面積が１００ｍ^２／ｇを超えると大幅な低下を示した。このため、内装材１０の多孔質皮膜１３の比表面積を１０〜１００ｍ^２／ｇの範囲に設定することにより、内装材１０の使用場所及び使用方法に応じて摩耗耐久性を示す内装材１０を提供することができる。
ここで、比表面積が１０〜１００ｍ^２／ｇとなるように作製した多孔質皮膜１３の表面に開口して存在する気孔１４の径を、例えば、水銀圧入法により求めると、０．１〜１０μｍ（気孔を円筒形と仮定したときの円筒の直径）となった。 Interior materials were prepared by changing the specific surface area of the porous film, and the adsorption performance of the anticancer agent and the wear durability of the porous film were evaluated. As a result, if the specific surface area of the porous film is less than 10 m ² / g, the anti-cancer agent adsorption performance is low, and if the specific surface area of the porous film is 10 m ² / g or more, the anti-cancer agent increases with the increase of the specific surface area. It was confirmed that the adsorption performance of the agent was improved. On the other hand, the wear resistance of the porous film tended to decrease with an increase in the specific surface area, and when the specific surface area exceeded 100 m ² / g, it showed a significant decrease. Therefore, by setting the specific surface area of the porous film 13 of the interior material 10 in the range of 10 to 100 m ² / g, the interior material 10 exhibiting abrasion resistance can be obtained depending on the place and method of use of the interior material 10. Can be provided.
Here, when the diameter of the pores 14 that are present on the surface of the porous coating 13 that has been prepared to have a specific surface area of 10 to 100 m ² / g is determined by, for example, the mercury intrusion method, it is 0.1 to 10 μm. (The diameter of the cylinder assuming that the pores are cylindrical).

図１に示すように、多孔質皮膜１３の表面には、可視光の照射により光触媒活性を発現する二酸化チタン粒子１２が露出している。ここで、二酸化チタン粒子１２をルチル型とすることで、二酸化チタン粒子１２の溶射時における熱的変化を防止することができる。
また、可視光（自然光（太陽光）や照明器具からの照明光）の照射により二酸化チタン粒子１２に光触媒活性を発現させるため、二酸化チタン粒子１２の表面には、可視光の照射により電子を励起して、二酸化チタン粒子１２を構成しているチタン原子に供給する金属原子を有する電子供与体１５が担持されている。このため、内装材１０（多孔質皮膜１３）の表面に可視光が照射されると、チタン原子の価数は４価から３価に減少し、電子を放出した金属原子の価数は１だけ増加する。その結果、二酸化チタン粒子１２の表面では抗がん剤の還元反応が、電子供与体１５の表面では抗がん剤の酸化反応がそれぞれ生じ、抗がん剤は分解されて失活する。 As shown in FIG. 1, titanium dioxide particles 12 that exhibit photocatalytic activity upon irradiation with visible light are exposed on the surface of the porous film 13. Here, by making the titanium dioxide particles 12 a rutile type, it is possible to prevent thermal changes during the thermal spraying of the titanium dioxide particles 12.
Further, in order to cause the titanium dioxide particles 12 to exhibit a photocatalytic activity by irradiation with visible light (natural light (sunlight) or illumination light from a lighting device), electrons are excited on the surface of the titanium dioxide particles 12 by irradiation with visible light. Then, the electron donor 15 having a metal atom to supply to the titanium atom constituting the titanium dioxide particle 12 is carried. Therefore, when the surface of the interior material 10 (porous film 13) is irradiated with visible light, the valence of titanium atoms decreases from 4 to 3 and the valence of the metal atoms that have emitted electrons is only 1. To increase. As a result, a reduction reaction of the anticancer agent occurs on the surface of the titanium dioxide particles 12 and an oxidation reaction of the anticancer agent occurs on the surface of the electron donor 15, and the anticancer agent is decomposed and deactivated.

抗がん剤を吸着した多孔質皮膜１３では、抗がん剤の分解は多孔質皮膜１３の表層部（表面から可視光が進入する範囲）で行われるが、表層部の抗がん剤が分解されると、多孔質皮膜１３の表層部と内部との間に抗がん剤の濃度勾配が発生し、多孔質皮膜１３の内部に吸着されていた抗がん剤は表層部に向けて移動する。このため、内装材１０の表面に可視光が照射し、かつ内装材１０（多孔質皮膜１３）が抗がん剤に曝されていない場合は、以前に吸着された抗がん剤が多孔質皮膜１３の内部から表層部に移動し、抗がん剤の分解が進行する。その結果、内装材１０（多孔質皮膜１３）内に抗がん剤が蓄積されることはなく、内装材１０（多孔質皮膜１３）の抗がん剤に対する吸着能力を、長期間に亘って維持することができる。 In the porous film 13 having the anti-cancer agent adsorbed, the decomposition of the anti-cancer agent is carried out in the surface layer part of the porous film 13 (the range where visible light enters from the surface). When decomposed, a concentration gradient of the anticancer agent is generated between the surface layer and the inside of the porous film 13, and the anticancer agent adsorbed inside the porous film 13 is directed toward the surface layer. Moving. Therefore, when the surface of the interior material 10 is irradiated with visible light and the interior material 10 (the porous film 13) is not exposed to the anticancer agent, the previously adsorbed anticancer agent is porous. It moves from the inside of the film 13 to the surface layer, and the decomposition of the anticancer agent proceeds. As a result, the anticancer agent is not accumulated in the interior material 10 (porous film 13), and the adsorption capacity of the interior material 10 (porous film 13) for the anticancer agent is maintained for a long period of time. Can be maintained.

電子供与体１５は、鉄、銅、ニッケル、又はクロムを含む金属の水酸化物、オキシ酸化物、及び酸化物の少なくとも１種である。即ち、図１に示すように、二酸化チタン粒子１２には、可視光に応答して電子を供給する電子供与体１５と、可視光に応答しない生成物１６が担持される。そして、電子供与体１５に含まれる金属の成分量は、多孔質皮膜１３を形成しているチタン成分量に対して、０．０５〜３質量％に設定されている。チタン成分量に対して金属の成分量が０．０５質量％未満では、チタン原子に供給される電子が少なく二酸化チタン粒子１２の表面における還元反応量が低下するため好ましくない。一方、チタン成分量に対して金属の成分量が３質量％を超えると、金属成分量に対するチタン成分量が相対的に低下し還元反応量が低下するため好ましくない。このため、電子供与体１５に含まれる金属の成分量を、多孔質皮膜１３に含まれるチタン成分量に対して、０．０５〜３質量％の範囲に設定する。 The electron donor 15 is at least one of a hydroxide, an oxyoxide, and an oxide of a metal containing iron, copper, nickel, or chromium. That is, as shown in FIG. 1, the titanium dioxide particles 12 carry an electron donor 15 that supplies electrons in response to visible light and a product 16 that does not respond to visible light. The amount of the metal component contained in the electron donor 15 is set to 0.05 to 3 mass% with respect to the amount of the titanium component forming the porous film 13. When the amount of the metal component is less than 0.05 mass% with respect to the amount of the titanium component, the number of electrons supplied to the titanium atom is small and the reduction reaction amount on the surface of the titanium dioxide particles 12 is reduced, which is not preferable. On the other hand, if the amount of the metal component exceeds 3 mass% with respect to the amount of the titanium component, the amount of the titanium component relative to the amount of the metal component relatively decreases, and the reduction reaction amount decreases, which is not preferable. Therefore, the amount of the metal component contained in the electron donor 15 is set within the range of 0.05 to 3 mass% with respect to the amount of the titanium component contained in the porous film 13.

続いて、本発明の一実施の形態に係る内装材の製造方法について説明する。
図１に示すように、内装材１０は、基材１１と、表側が抗がん剤に曝露される空間に露出し、裏側が基材１１の表面に固着している多孔質皮膜１３とを有し、二酸化チタン粒子１２と金属化合物とを有する混合物を溶射フレーム中に供給して混合物を溶射フレームの流れに乗せ、金属化合物の加熱変化で生成した電子供与体１５を二酸化チタン粒子１２の表面に担持させながら、電子供与体１５を担持した二酸化チタン粒子１２を基材１１の表面に衝突させて多孔質皮膜１３を形成している。そして、多孔質皮膜１３に対する封孔を防止して、多孔質皮膜１３の形成時の多孔質状態を維持することにより、多孔質皮膜１３に電子供与体１５を担持した二酸化チタン粒子１２を露出させている。以下、詳細に説明する。 Then, the manufacturing method of the interior material which concerns on one embodiment of this invention is demonstrated.
As shown in FIG. 1, the interior material 10 includes a base material 11 and a porous film 13 having a front side exposed in a space exposed to an anticancer agent and a back side fixed to a surface of the base material 11. A mixture containing titanium dioxide particles 12 and a metal compound is supplied into the flame spraying frame, the mixture is placed on the flow of the flame spraying frame, and the electron donor 15 generated by the heating change of the metal compound is added to the surface of the titanium dioxide particle 12. While the titanium dioxide particles 12 carrying the electron donor 15 are made to collide with the surface of the base material 11, the porous film 13 is formed. The titanium dioxide particles 12 carrying the electron donor 15 are exposed on the porous film 13 by preventing the porous film 13 from being sealed and maintaining the porous state when the porous film 13 is formed. ing. The details will be described below.

二酸化チタン粒子１２の表面に抗がん剤を効率的に吸着させるためには、二酸化チタン粒子１２の比表面積を大きく（二酸化チタン粒子１２の粒径を小さく）することが好ましい。また、溶射時に、溶射フレーム中で金属化合物から、二酸化チタン粒子１２に担持可能なサイズの電子供与体１５（金属の水酸化物、オキシ酸化物、又は酸化物）を、効率的に生成させるには、金属化合物を二酸化チタン粒子１２の粒径よりも微細にすると共に、二酸化チタン粒子１２に対して均一に分散させる必要がある。一方、二酸化チタン粒子１２の粒径が小さくなるほど、溶射フレーム中での熱による変質を受け易くなる。そこで、二酸化チタン粒子１２と金属化合物とを水に混合してスラリー状の混合物を形成することにより、溶射時の熱による影響で二酸化チタン粒子１２が変質するのを抑制した。 In order to efficiently adsorb the anticancer agent on the surface of the titanium dioxide particles 12, it is preferable to make the specific surface area of the titanium dioxide particles 12 large (the particle diameter of the titanium dioxide particles 12 small). Further, at the time of thermal spraying, an electron donor 15 (metal hydroxide, oxyoxide, or oxide) having a size that can be supported by the titanium dioxide particles 12 is efficiently generated from the metal compound in the thermal spray frame. It is necessary to make the metal compound finer than the particle size of the titanium dioxide particles 12 and to uniformly disperse the metal compound in the titanium dioxide particles 12. On the other hand, the smaller the particle size of the titanium dioxide particles 12, the more susceptible it is to alteration by heat in the thermal spray frame. Therefore, by mixing the titanium dioxide particles 12 and the metal compound with water to form a slurry-like mixture, it is possible to suppress the deterioration of the titanium dioxide particles 12 due to the influence of heat during thermal spraying.

これにより、１次粒子径が１０〜５０ｎｍの二酸化チタン粒子１２を溶射することができ、比表面積が１０〜１００ｍ^２／ｇ、気孔１４の径が０．１〜１０μｍの多孔質皮膜１３を基材１１上に形成することが可能になる。
ここで、金属化合物として水溶性金属錯体又は水溶性金属塩を用いることで、金属はプラスイオンの状態で混合物中に存在することになって、二酸化チタン粒子１２に対して均一に分散することができる。更に、溶射フレーム中では、金属のプラスイオンは、スラリー状の混合物中に含まれる水、及び空気中の酸素と容易に反応して水酸化物、オキシ酸化物、及び酸化物を生成し（金属の種類により、生成する水酸化物、オキシ酸化物、及び酸化物の生成割合は異なる）、二酸化チタン粒子１２に担持されると考えられる。なお、水溶性金属錯体又は水溶性金属塩中の非金属部分（マイナスイオンを示す原子又は原子団）は溶射の熱によって揮発し大気中に拡散し、水酸化物、オキシ酸化物、若しくは酸化物中には残存しないと考えられる。 Thereby, the titanium dioxide particles 12 having a primary particle diameter of 10 to 50 nm can be sprayed, the specific surface area is 10 to 100 m ² / g, and the diameter of the pores 14 is 0.1 to 10 μm. It becomes possible to form it on the material 11.
Here, by using a water-soluble metal complex or a water-soluble metal salt as the metal compound, the metal is present in the mixture in the form of positive ions, and can be uniformly dispersed in the titanium dioxide particles 12. it can. Further, in the thermal spray flame, metal positive ions easily react with water contained in the slurry-like mixture and oxygen in the air to form hydroxides, oxyoxides, and oxides (metal It is considered that the generated hydroxides, oxyoxides, and oxides are different depending on the type of), and they are supported by the titanium dioxide particles 12. The non-metal part (atoms or atomic groups showing negative ions) in the water-soluble metal complex or the water-soluble metal salt is volatilized by the heat of thermal spraying and diffused into the atmosphere to form a hydroxide, oxyoxide, or oxide. It is thought that it does not remain inside.

例えば、金属化合物として、水溶性金属塩の一例である塩化鉄（ＦｅＣｌ_３）を使用した場合、鉄成分はスラリー状の混合物中では鉄イオン（３価）として存在しているので、混合物を溶射フレーム中に混入すると、鉄イオンの一部は水と反応してナノサイズのオキシ水酸化鉄ＦｅＯ（ＯＨ）を生成すると共に二酸化チタン粒子１２の表面に担持され、鉄イオンの残部は水と反応してナノサイズのＦｅＯ（ＯＨ）を生成し、更に酸化されてナノサイズの酸化鉄Ｆｅ_２Ｏ_３となって二酸化チタン粒子１２の表面に担持される。
そして、二酸化チタン粒子１２に可視光が照射されると、オキシ水酸化鉄は価電子帯の電子を伝導帯に励起させ（オキシ水酸化鉄が電子供与体１５、酸化鉄が可視光に応答しない生成物１６にそれぞれ対応する）、伝導帯に励起された電子はチタン原子に移動する。その結果、ＦｅＯ（ＯＨ）中の鉄は酸化力を有する４価に、電子が移動してきたチタン原子は還元力を有する３価になって、それぞれ光触媒活性を示すことになる。 For example, when iron chloride (FeCl ₃ ) which is an example of a water-soluble metal salt is used as the metal compound, the iron component exists as iron ions (trivalent) in the slurry-like mixture, and thus the mixture is sprayed. When mixed in the frame, part of iron ions reacts with water to generate nano-sized iron oxyhydroxide FeO (OH) and is carried on the surface of titanium dioxide particles 12, and the rest of iron ions reacts with water. Then, nano-sized FeO (OH) is generated and further oxidized to form nano-sized iron oxide Fe ₂ O ₃ which is carried on the surface of the titanium dioxide particles 12.
When the titanium dioxide particles 12 are irradiated with visible light, the iron oxyhydroxide excites electrons in the valence band into the conduction band (iron oxyhydroxide does not serve as the electron donor 15 and iron oxide does not respond to visible light). Electrons excited in the conduction band move to titanium atoms (corresponding to products 16, respectively). As a result, the iron in FeO (OH) becomes tetravalent, which has an oxidizing power, and the titanium atom to which the electron has moved becomes trivalent, which has a reducing power, and each exhibits photocatalytic activity.

（内装材の作製）
１次粒子径が３０ｎｍのルチル型の二酸化チタン粒子と、純度が９８％の無水塩化鉄（ＦｅＣｌ_３）を水に加えてスラリー状の混合物を作製した。ここで、無水塩化鉄の量は、鉄の成分量が、二酸化チタン粒子のチタン成分量に対して０．３質量％となるように、水の量は、混合物中の二酸化チタン粒子の質量が５質量％となるようにそれぞれ調整した。また、基材には、縦４５０ｍｍ、横４５０ｍｍ、厚さ３ｍｍのタイル（材質は塩化ビニル）を使用した。 (Production of interior materials)
Rutile-type titanium dioxide particles having a primary particle diameter of 30 nm and anhydrous iron chloride (FeCl ₃ ) having a purity of 98% were added to water to prepare a slurry-like mixture. Here, the amount of anhydrous iron chloride is such that the amount of iron component is 0.3% by mass with respect to the amount of titanium component of titanium dioxide particles, and the amount of water is the amount of titanium dioxide particles in the mixture. Each was adjusted to be 5% by mass. As the base material, a tile (material: vinyl chloride) having a length of 450 mm, a width of 450 mm, and a thickness of 3 mm was used.

基材の非溶射面側を保持台に当接させ、真空吸引により固定した。そして、高速溶射装置（特許第３９７８５１２号公報参照）に設けた溶射ガンの先端部にスラリー状の混合物を溶射フレーム中に供給するためのスラリー混合部を取付け、スラリー混合部のフレームガイド部内を通過する溶射フレーム中に混合物を１分間に５０〜３００ｇの割合で噴出させ、フレームガイド部の先端から５０〜３００ｍｍ離れた位置に固定した基材の表面上に厚さ１μｍの多孔質皮膜を形成することにより内装材を作製した。ここで、溶射フレームの温度は２８００℃、溶射フレームの速度は１２００ｍｍ／秒であり、溶射ガンは基材に対して平行にピッチ５ｍｍで１０００ｍｍ／秒の速度で走査させた。また、塩ビタイル表面の温度がガラス移転温度（８２℃）に達する前に溶射を終了させた。 The non-sprayed surface side of the base material was brought into contact with the holding base and fixed by vacuum suction. Then, a slurry mixing section for supplying a slurry-like mixture into the thermal spray frame is attached to the tip of the thermal spray gun provided in the high-speed thermal spraying device (see Japanese Patent No. 3978512), and passes through the frame guide section of the slurry mixing section. The mixture is jetted into the thermal spray frame at a rate of 50 to 300 g per minute to form a porous film having a thickness of 1 μm on the surface of the base material fixed at a position 50 to 300 mm away from the tip of the frame guide portion. Thus, an interior material was produced. Here, the temperature of the thermal spray frame was 2800 ° C., the speed of the thermal spray frame was 1200 mm / sec, and the thermal spray gun was made to scan parallel to the base material at a pitch of 5 mm and at a velocity of 1000 mm / sec. Further, the thermal spraying was terminated before the surface temperature of the PVC tile reached the glass transfer temperature (82 ° C).

溶射終了後、真空吸引を解除し、内装材（多孔質皮膜が形成された基材）を保持台から取り外し、多孔質皮膜の温度が３０℃以下になるまで室温中で冷却した。冷却が終了した内装材は、高圧洗浄機を用いて洗浄し、空気を噴きつけて付着している水を除去した後、自然乾燥させた。
なお、内装材から多孔質皮膜を分離して、比表面積と表面に開口する気孔の径をそれぞれ測定すると、比表面積は３０ｍ^２／ｇ、気孔の径は１μｍであった。 After the thermal spraying was completed, the vacuum suction was released, the interior material (the base material on which the porous film was formed) was removed from the holding table, and cooled at room temperature until the temperature of the porous film reached 30 ° C or lower. The cooled interior material was washed with a high-pressure washing machine, air was blown to remove water adhering to the interior material, and then the interior material was naturally dried.
When the porous film was separated from the interior material and the specific surface area and the diameter of the pores opened on the surface were measured, the specific surface area was 30 m ² / g and the pore diameter was 1 μm.

抗がん剤として以下に示すフルオロウラシル、シクロホスファミド、パクリタキセル、及びドキソルビシン塩酸塩を用いて、内装材による分解状況を調べた。
（実施例１）
内装材の多孔質皮膜に、濃度が１μｇ／ｍリットルのフルオロウラシル溶液を１ｍリットル塗布し、多孔質皮膜の表面に照度が６００ｌｘ（ルクス）の可視光（光源は蛍光灯）と、照度が１０００ｌｘの可視光（光源は蛍光灯）を１、６、１２、２４、４８時間それぞれ照射した後、内装材（多孔質皮膜）中のフルオロウラシルの残存量を求める分解試験を３回実施した。３回の分解試験からそれぞれ得られる残存率の平均値を図２に示す。
また、比較例１として、基材の表面に濃度が１μｇ／ｍリットルのフルオロウラシル溶液を１ｍリットル塗布し、塗布側の表面に照度が６００ｌｘの可視光と、照度が１０００ｌｘの可視光を１、６、１２、２４、４８時間それぞれ照射した後、基材に付着しているフルオロウラシルの残存量を求める分解試験を３回実施した。３回の分解試験からそれぞれ得られる残存率の平均値を図２に合わせて示す。 Fluorouracil, cyclophosphamide, paclitaxel, and doxorubicin hydrochloride shown below were used as anticancer agents, and the state of decomposition by the interior material was examined.
(Example 1)
1 ml of fluorouracil solution having a concentration of 1 μg / ml was applied to the porous film of the interior material, and the surface of the porous film had a visible light of 600 lx (lux) and a light source of 1000 lx. After irradiating with visible light (a light source is a fluorescent lamp) for 1, 6, 12, 24, and 48 hours, respectively, a decomposition test for determining the residual amount of fluorouracil in the interior material (porous film) was performed three times. The average value of the residual rate obtained from each of the three decomposition tests is shown in FIG.
Further, as Comparative Example 1, 1 ml of a fluorouracil solution having a concentration of 1 μg / ml was applied to the surface of the base material, and the visible light having an illuminance of 600 lx and the visible light having an illuminance of 1000 lx were applied to the surface of the application side at 1 to 6 , 12, 24, and 48 hours, the decomposition test for determining the residual amount of fluorouracil adhering to the substrate was carried out three times. The average value of the residual rate obtained from each of the three decomposition tests is shown in FIG.

比較例１では、可視光の照射時間を増加にしてもフルオロウラシルの継続的な残存率の低下（分解の進行）が認められず、可視光の照度を変化させてもフルオロウラシルの残存率の低下に差は認められなかった。一方、実施例１では、可視光の照射時間の増加に伴って残存率が低下（分解が進行）すること、残存率の低下は照度が高いほど顕著であることが認められた。その結果、可視光により生じる二酸化チタンの光触媒活性を用いて、フルオロウラシルの分解が可能であることが分かった。 In Comparative Example 1, even if the irradiation time of visible light was increased, a continuous decrease in the residual ratio of fluorouracil (progress of decomposition) was not observed, and even if the illuminance of visible light was changed, the residual ratio of fluorouracil decreased. No difference was found. On the other hand, in Example 1, it was confirmed that the residual rate decreased (decomposition proceeded) as the irradiation time of visible light increased, and that the decreased residual rate was more remarkable as the illuminance was higher. As a result, it was found that fluorouracil can be decomposed by using the photocatalytic activity of titanium dioxide generated by visible light.

（実施例２）
内装材の多孔質皮膜に、濃度が１μｇ／ｍリットルのシクロホスファミド溶液を１ｍリットル塗布し、実施例１と同じ条件で、内装材（多孔質皮膜）中のシクロホスファミドの残存量を求める分解試験を３回実施した。３回の分解試験からそれぞれ得られる残存率の平均値を図３に示す。
また、比較例２として、基材の表面に濃度が１μｇ／ｍのシクロホスファミド溶液を１ｍリットル塗布し、比較例１と同じ条件で、基材に付着しているシクロホスファミドの残存量を求める分解試験を３回実施した。３回の分解試験からそれぞれ得られる残存率の平均値を図３に合わせて示す。 (Example 2)
1 ml of a cyclophosphamide solution having a concentration of 1 μg / ml was applied to the porous film of the interior material, and the residual amount of cyclophosphamide in the interior material (porous film) was applied under the same conditions as in Example 1. Was carried out three times. The average value of the residual rate obtained from each of the three decomposition tests is shown in FIG.
Further, as Comparative Example 2, 1 ml of a cyclophosphamide solution having a concentration of 1 μg / m was applied to the surface of the base material, and the cyclophosphamide remaining on the base material remained under the same conditions as in Comparative Example 1. The decomposition test for determining the amount was carried out three times. The average value of the residual rate obtained from each of the three decomposition tests is shown in FIG.

比較例２では、可視光の照射時間を増加にしてもシクロホスファミドの継続的な残存率の低下が認められず、可視光の照度を変化させてもシクロホスファミドの残存率の低下に差は認められなかった。一方、実施例２では、可視光の照射時間の増加に伴って残存率が低下することが認められた。その結果、可視光により生じる二酸化チタンの光触媒活性を用いて、シクロホスファミドの分解が可能であることが分かった。
なお、シクロホスファミドの場合、照度の違いが残存率の低下に及ぼす影響は認められなかった。 In Comparative Example 2, a continuous decrease in the residual rate of cyclophosphamide was not observed even when the irradiation time of visible light was increased, and the residual rate of cyclophosphamide was decreased even when the illuminance of visible light was changed. There was no difference in On the other hand, in Example 2, it was confirmed that the residual rate decreased as the irradiation time of visible light increased. As a result, it was found that cyclophosphamide can be decomposed by using the photocatalytic activity of titanium dioxide generated by visible light.
In the case of cyclophosphamide, no effect of the difference in illuminance on the reduction of the residual rate was observed.

（実施例３）
内装材の多孔質皮膜に、濃度が１μｇ／ｍリットルのパクリタキセル溶液を１ｍリットル塗布し、実施例１と同じ条件で、内装材（多孔質皮膜）中のパクリタキセルの残存量を求める分解試験を３回実施した。３回の分解試験からそれぞれ得られる残存率の平均値を図４に示す。
また、比較例３として、基材の表面に濃度が１μｇ／ｍのパクリタキセル溶液を１ｍリットル塗布し、比較例１と同じ条件で、基材に付着しているパクリタキセルの残存量を求める分解試験を３回実施した。３回の分解試験からそれぞれ得られる残存率の平均値を図４に合わせて示す。 (Example 3)
1 ml of a paclitaxel solution having a concentration of 1 μg / ml was applied to the porous film of the interior material, and the decomposition test for determining the residual amount of paclitaxel in the interior material (porous film) was conducted under the same conditions as in Example 1 (3). Conducted once. The average value of the residual rate obtained from each of the three decomposition tests is shown in FIG.
Further, as Comparative Example 3, a decomposition test was carried out in which 1 ml of a paclitaxel solution having a concentration of 1 μg / m was applied to the surface of the base material, and the remaining amount of paclitaxel adhering to the base material was obtained under the same conditions as in Comparative Example 1. It was carried out three times. The average value of the residual rate obtained from each of the three decomposition tests is shown in FIG.

比較例３では、可視光の照射時間を増加にしてもパクリタキセルの継続的な残存率の低下が認められず、可視光の照度を変化させてもパクリタキセルの残存率の低下に差は認められなかった。一方、実施例３では、可視光の照射時間の増加に伴って残存率が低下することが認められた。その結果、可視光により生じる二酸化チタンの光触媒活性を用いて、パクリタキセルの分解が可能であることが分かった。
なお、パクリタキセルの場合、照度の違いが残存率の低下に及ぼす影響は認められなかった。 In Comparative Example 3, no continuous decrease in the paclitaxel residual rate was observed even when the visible light irradiation time was increased, and no difference was observed in the decrease in the paclitaxel residual rate even when the illuminance of visible light was changed. It was On the other hand, in Example 3, it was confirmed that the residual rate was decreased as the visible light irradiation time was increased. As a result, it was found that the photocatalytic activity of titanium dioxide generated by visible light can be used to decompose paclitaxel.
In the case of paclitaxel, the effect of the difference in illuminance on the reduction of the residual rate was not recognized.

（実施例４）
内装材の多孔質皮膜に、濃度が１μｇ／ｍリットルのドキソルビシン塩酸塩溶液を１ｍリットル塗布し、実施例１と同じ条件で、内装材（多孔質皮膜）中のドキソルビシン塩酸塩の残存量を求める分解試験を３回実施した。３回の分解試験からそれぞれ得られる残存率の平均値を図５に示す。
また、比較例４として、基材の表面に濃度が１μｇ／ｍのドキソルビシン塩酸塩溶液を１ｍリットル塗布し、比較例１と同じ条件で、基材に付着しているドキソルビシン塩酸塩の残存量を求める分解試験を３回実施した。３回の分解試験からそれぞれ得られる残存率の平均値を図５に合わせて示す。 (Example 4)
1 ml of a doxorubicin hydrochloride solution having a concentration of 1 μg / ml was applied to the porous film of the interior material, and the residual amount of doxorubicin hydrochloride in the interior material (porous film) was determined under the same conditions as in Example 1. The decomposition test was performed 3 times. The average value of the residual rate obtained from each of the three decomposition tests is shown in FIG.
Further, as Comparative Example 4, 1 ml of a doxorubicin hydrochloride solution having a concentration of 1 μg / m was applied to the surface of the base material, and the remaining amount of doxorubicin hydrochloride adhering to the base material was measured under the same conditions as in Comparative Example 1. The required decomposition test was performed three times. The average value of the residual rate obtained from each of the three decomposition tests is shown in FIG.

比較例４では、可視光の照射時間を増加にしてもドキソルビシン塩酸塩の継続的な残存率の低下が認められず、可視光の照度を変化させてもドキソルビシン塩酸塩の残存率の低下に差は認められなかった。一方、実施例４では、可視光の照射時間の増加に伴って残存率が低下することが認められた。その結果、可視光により生じる二酸化チタンの光触媒活性を用いて、ドキソルビシン塩酸塩の分解が可能であることが分かった。
なお、ドキソルビシン塩酸塩の場合、照度の違いが残存率の低下に及ぼす影響は認められなかった。 In Comparative Example 4, a continuous decrease in the doxorubicin hydrochloride residual rate was not observed even when the visible light irradiation time was increased, and there was a difference in the decrease in the doxorubicin hydrochloride residual rate even when the visible light illuminance was changed. Was not recognized. On the other hand, in Example 4, it was confirmed that the residual rate was decreased as the irradiation time of visible light was increased. As a result, it was found that the photocatalytic activity of titanium dioxide generated by visible light can be used to decompose doxorubicin hydrochloride.
In addition, in the case of doxorubicin hydrochloride, the effect of the difference in illuminance on the reduction of the survival rate was not observed.

以上、本発明を、実施の形態を参照して説明してきたが、本発明は何ら上記した実施の形態に記載した構成に限定されるものではなく、特許請求の範囲に記載されている事項の範囲内で考えられるその他の実施の形態や変形例も含むものである。
更に、本実施の形態とその他の実施の形態や変形例にそれぞれ含まれる構成要素を組合わせたものも、本発明に含まれる。
例えば、本実施の形態では、基材の表面に形成する多孔質皮膜を電子供与体が担持された二酸化チタン粒子で構成したが、電子供与体が担持された二酸化チタン粒子と、例えば、銀、亜鉛、アルミニウム、又はコバルト等の抗菌金属の化合物とを用いて構成することもできる。多孔質皮膜が電子供与体が担持された二酸化チタン粒子と抗菌金属の化合物とを有するので、内装材（多孔質皮膜）により抗がん剤を分解すると共に、抗がん剤に曝露される空間内の浮遊菌に対して、内装材の表面を除菌状態、抗菌状態にすることができる。 Although the present invention has been described above with reference to the exemplary embodiments, the present invention is not limited to the configurations described in the above-described exemplary embodiments, and includes the matters described in the claims. It also includes other embodiments and modifications that are conceivable within the scope.
Further, the present invention also includes a combination of the constituent elements respectively included in the present embodiment and other embodiments and modifications.
For example, in the present embodiment, the porous film formed on the surface of the substrate is composed of titanium dioxide particles carrying an electron donor, but titanium dioxide particles carrying an electron donor and, for example, silver, It can also be configured using a compound of an antibacterial metal such as zinc, aluminum, or cobalt. Since the porous film has titanium dioxide particles supporting an electron donor and a compound of an antibacterial metal, the interior material (porous film) decomposes the anticancer agent and the space exposed to the anticancer agent The surface of the interior material can be sterilized and antibacterial with respect to the floating bacteria therein.

１０：内装材、１１：基材、１２：二酸化チタン粒子、１３：多孔質皮膜、１４：気孔、１５：電子供与体、１６：生成物 10: interior material, 11: base material, 12: titanium dioxide particles, 13: porous film, 14: pores, 15: electron donor, 16: product

Claims

A base material and a porous film having a thickness of 0.5 to 3 μm, which is fixed to the surface of the base material and has titanium dioxide particles that exhibit photocatalytic activity when exposed to visible light;
An interior material, wherein the titanium dioxide particles are exposed in the porous film and exposed to an existing anticancer agent.

The interior material according to claim 1, wherein the porous film has a specific surface area of 10 to 100 m ² / g, and pores opening on the surface have a diameter of 0.1 to 10 μm.

The interior material according to claim 1 or 2, wherein the titanium dioxide particles are of the rutile type, and the surface thereof carries an electron donor that excites electrons by irradiation of visible light to supply titanium atoms. Interior material to be.

The interior material according to claim 3, wherein the electron donor is at least one of a hydroxide, an oxyoxide, and an oxide of a metal containing iron, copper, nickel, or chromium, and the amount of the metal component. Is an interior material characterized by being set to 0.05 to 3 mass% with respect to the amount of titanium component of the porous film.

A method for producing an interior material having a base material and a porous film in which the front side is exposed in a space exposed to an anticancer agent, and the back side is fixed to the surface of the base material,
A mixture containing titanium dioxide particles and a metal compound is supplied into a flame spraying frame, the mixture is placed on the flow of the flame spraying frame, and an electron donor produced by the heating change of the metal compound is supported on the surface of the titanium dioxide particles. While colliding, the titanium dioxide particles carrying the electron donor are made to collide with the surface of the base material to form the porous film having a thickness of 0.5 to 3 μm ,
The titanium dioxide particles carrying the electron donor are exposed in the porous film by preventing sealing of the porous film and maintaining the porous state at the time of forming the porous film. And a method of manufacturing interior materials.